InvestSMART

Recce Pharmaceuticals Ltd (ASX:RCE)

ALERT: Price-sensitive ASX Announcement for RCE
Current share price for RCE : $0.375 -0.045 (-10.71%)+
Announcement
Release
29 Aug 2025 7:27PM
Price at Release
$0.420
Full Release
download
Summary
Recce Pharmaceuticals Ltd reported a loss of $21,428,089 for the financial year ending 30 June 2025, driven by advancements in its synthetic anti-infective program and increased spending on research and development. Notable achievements include successful Phase II clinical trials of its lead compound R327G, international approvals for Phase 3 trials, a US$2 million grant from the US Department of Defence, and significant capital raising efforts. The company also expanded its patent portfolio with new grants in multiple countries.
Key Points
  • Recce Pharmaceuticals Ltd reported a loss of $21,428,089 for the financial year ending 30 June 2025, compared to a loss of $17,661,714 for the previous year.
  • The company made significant advancements in its synthetic anti-infective program, particularly with its lead compound R327G.
  • Phase II clinical trials of R327G showed promising results, with 86% of patients having a successful clinical response after 7 days, and 93% after 14 days.
  • The company received various approvals, including from the Indonesian Drug and Food Regulatory Authority and the Human Research Ethics Committee, to commence Phase 3 clinical trials.
  • Recce was awarded a US$2 million grant from the US Department of Defence for R327G as a treatment for burn wound infections.
  • The company successfully raised A$15.8 million through private placements and entitlement offers.
  • Recce received a cash refund of AUD $6,738,274 as an R&D Tax Incentive rebate from the Australian Taxation Office.
  • The company continued to expand its intellectual property portfolio with new patents in Australia, China, and Japan.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.